Key Takeaways
- Cardinal Health increased its full-year adjusted EPS outlook to $10.70โ$10.80 from a prior range of $10.15โ$10.35.
- Third-quarter adjusted EPS of $3.17 surpassed Wall Street’s $2.79 consensus estimate.
- Quarterly revenue increased 11% year-over-year to $60.9 billion but fell below the $62.1 billion analyst expectation.
- Net income declined to $399 million from $506 million due to a $184 million goodwill impairment charge.
- CAH shares advanced 1.6% in Thursday’s premarket session.
Cardinal Health has upgraded its annual profit projection for the second consecutive time this fiscal year, a move that resonated positively with investors. Shares jumped 1.6% to $205.99 in premarket activity Thursday.
The healthcare distributor now anticipates adjusted earnings between $10.70 and $10.80 per share for fiscal year 2026. This represents a meaningful upgrade from the $10.15 to $10.35 range provided in February. The Street consensus had centered around $10.31 per share.
While the raised guidance captured investors’ attention, the third-quarter results themselves presented a more nuanced picture.
On the earnings front, adjusted EPS of $3.17 significantly exceeded the $2.79 analyst forecast. This marked outperformance delivered the positive surprise investors appreciate.
Revenue growth, however, disappointed. Total sales climbed 11% from the prior-year period to $60.9 billion, yet came up short of the $62.1 billion consensus expectation.
The pharmaceutical and specialty solutions division accounted for the bulk of growth, generating $56.1 billion in revenueโan 11% increase compared to last year’s corresponding quarter.
Meanwhile, the global medical products and distribution segment struggled. Sales in this division remained essentially unchanged year-over-year, hampered by reduced distribution volumes.
Bottom Line Pressure
Net income fell to $399 million from $506 million in the same quarter last year. The primary driver was a $184 million pretax goodwill impairment charge.
This charge related to Cardinal’s oncology practice alliance and its Integrated Oncology Network acquisition completed in late 2024.
While goodwill impairments don’t impact cash flow directly, they indicate that an acquired business isn’t delivering the value anticipated at the time of purchase. It’s a red flag worth monitoring.
Evercore ISI analyst Elizabeth Anderson characterized the quarter as “solid,” pointing out that the pharmaceutical revenue shortfall stemmed mainly from wholesale acquisition cost dynamicsโa passthrough accounting matter rather than an underlying business weakness.
Specialty Pharmaceuticals Drive Forward Guidance
Cardinal Health, alongside competitors Cencora and McKesson, continues benefiting from robust demand for higher-margin specialty medications. Distribution of cancer treatments and autoimmune therapies represents an increasingly profitable segment.
The introduction of biosimilar alternatives for expired blockbuster drugs is also boosting volume. These segments enable distributors to capture superior margins compared to traditional generic medications.
Cardinal has been strategically expanding its specialty care presence through targeted acquisitions of physician practices and specialty networks. The Integrated Oncology Network transaction exemplified this strategic approach.
This strategy has encountered some challengesโevidenced by this quarter’s impairment charge. Nevertheless, management appears committed to this strategic direction.
The upgraded full-year guidanceโnow the second increase in consecutive quartersโreflects management’s optimism about performance in the remaining fiscal period.
Cardinal Health’s fiscal third quarter concluded on March 31. At the time of reporting, CAH shares traded 1.6% higher in premarket activity at $205.99.
